Publications by authors named "E Kudela"

Significant limitations of the reactive medical approach in breast cancer management are clearly reflected by alarming statistics recorded worldwide. According to the WHO updates, breast malignancies become the leading cancer type. Further, the portion of premenopausal breast cancer cases is permanently increasing and demonstrates particularly aggressive patterns and poor outcomes exemplified by young patients with triple-negative breast cancer that lacks targeted therapy.

View Article and Find Full Text PDF

Background: Cancer management faces multiple obstacles, including resistance to current therapeutic approaches. In the face of challenging microenvironments, cancer cells adapt metabolically to maintain their supply of energy and precursor molecules for biosynthesis and thus sustain rapid proliferation and tumor growth. Among the various metabolic adaptations observed in cancer cells, the altered glucose metabolism is the most widely studied.

View Article and Find Full Text PDF

Medicinal mushrooms have been used as a medicinal tool for many centuries and, nowadays, are used in the prevention and therapy of various diseases, including as an adjunct to cancer treatment. It is estimated that 14-16% of global cancer cases are caused by infectious events; one well-known infectious agent that leads to cancer is the human papillomavirus (HPV). HPV is responsible for more than 99.

View Article and Find Full Text PDF

Some estimates place the proportion of human malignancies attributable to viruses at between 15 and 20 percent. Viruses including the human papillomavirus are considered an interesting but controversial etiological risk factor for breast cancer. HPV infection is anticipated to be an early trigger in breast cancer carcinogenesis, followed by cumulative alterations over time ("hit and run" mechanism) through synergy with other environmental factors.

View Article and Find Full Text PDF
Article Synopsis
  • Triple-negative breast cancer is characterized by heterogeneity at various levels, including clinical and molecular, and is associated with poor clinical outcomes due to its aggressive nature and high rates of metastasis.
  • The complexity of the tumor immune microenvironment, along with genomic instability and mutated genes, impacts treatment strategies and prognosis, pointing to the potential of utilizing immunity-associated genes in developing prognostic indexes.
  • Ongoing research aims to improve targeted therapies and immunotherapy by combining treatments, such as immune checkpoint inhibitors with chemotherapy, to enhance patient survival rates and overcome therapeutic resistance.
View Article and Find Full Text PDF